# Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO

> **NCT03054766** · NA · COMPLETED · sponsor: **Beijing Hospital** · enrollment: 80 (actual)

## Conditions studied

- Branch Retinal Vein Occlusion
- Ranibizumab
- Laser Photocoagulation

## Interventions

- **PROCEDURE:** Ranibizumab combined macular laser
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT03054766
- **Lead sponsor:** Beijing Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-14
- **Primary completion:** 2018-02-01
- **Final completion:** 2019-01-28
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03054766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03054766, "Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03054766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*